GDP temperature monitoring requirements are often reduced to one question: did the medicine stay within range? In practice, Good Distribution Practice is broader. It is about preserving the quality and integrity of medicinal products while they are stored, handled, transported, received, returned, quarantined and reviewed.
For temperature monitoring, that means teams need more than a thermometer reading or a downloaded logger file. They need a record that shows what was monitored, which limits applied, whether a temperature excursion occurred, who was alerted, who acknowledged the event, and what evidence is available for later quality review.
KRYOS fits this workflow as the environmental evidence layer. It supports continuous temperature monitoring, configured thresholds, temperature alerts, acknowledgements, response notes, reports and exports. It can support GDP-oriented monitoring, but it does not make an organisation GDP compliant by itself. Product disposition, deviation handling, CAPA, SOPs, staff training, supplier qualification and final quality sign-off remain with the customer’s quality system.
What GDP means for temperature monitoring
Good Distribution Practice sets expectations for the distribution of medicinal products. In the EU context, GDP is used to help ensure that medicines are authorised, stored in the right conditions, protected from contamination, managed with appropriate stock turnover and delivered to the correct recipient in an acceptable timeframe. The European Medicines Agency GDP overview frames GDP around maintaining medicine quality throughout distribution.
For monitoring teams, the practical point is simple: medicines should be stored and transported under suitable conditions according to the product’s requirements. Those requirements may come from product labelling, manufacturer guidance, stability information, quality agreements, SOPs, or local regulatory expectations.
That is why GDP temperature monitoring requirements are not identical for every product or workflow. One product may require refrigerated storage. Another may require controlled ambient storage. Another may be especially sensitive to freezing. A warehouse zone, vehicle route, return area or receiving hold can each create a different quality question.
A useful GDP monitoring setup should help answer:
- what condition was required for the product or storage point
- which room, asset, vehicle, route, shipment, return area or quarantine point was monitored
- which upper and lower alarm limits were configured
- whether the event was too warm, too cold, a disconnection or another device issue
- when the event started and ended
- how long the exposure lasted
- what the minimum or maximum value was
- who received the alert
- who acknowledged the event
- what response note was recorded
- which report or export can be reviewed later.
GDP temperature monitoring is not only 2 to 8 degrees Celsius
Many refrigerated medicines are stored around 2 to 8 degrees Celsius, so that range appears frequently in GDP temperature monitoring conversations. It should still be treated as a common example, not a universal rule.
GDP-oriented monitoring can involve:
- controlled ambient rooms
- refrigerated cold rooms
- medicine refrigerators
- freezer rooms where relevant
- do-not-freeze products
- dispatch preparation and temporary holds
- loading bays
- transport vehicles
- monitored containers or boxes when configured
- receiving areas
- returns areas
- quarantine areas
- temporary holds
- humidity-sensitive areas where relevant.
The correct limits should be defined by the customer’s quality process. KRYOS can help apply configured limits, detect events, route alerts and preserve records. It does not decide the required storage condition for a medicinal product.
Storage requirements: rooms, zones and temporary holds
GDP monitoring often starts with storage, but storage is rarely just one cold room.
A pharmaceutical distributor, wholesaler, logistics provider or outsourced storage operation may have goods-in areas, controlled ambient rooms, refrigerated rooms, freezer rooms, picking zones, packing areas, dispatch holds, returns, quarantine, rejected deliveries awaiting review and temporary QA holds.
Each point can create a temperature record that may matter later. A product may remain stable in the main cold room but face exposure during receiving, picking, dispatch preparation or return review. If those points are not monitored, quality teams may have to reconstruct the temperature story after the fact.
A practical GDP temperature monitoring setup should map the storage workflow and decide which points need continuous monitoring, which can rely on documented checks, and which are controlled through SOPs or other procedures.
KRYOS can support storage monitoring by keeping readings, thresholds, alerts, response notes and exports tied to the relevant site, room, asset, zone or storage point where configured.
Transport requirements: dispatch to receiving
GDP temperature monitoring also applies during transport. The European Commission GDP guideline for medicinal products includes transport expectations, including that required storage conditions should be maintained during transportation and that customers should be provided with data demonstrating conditions during transport if requested.
In practical terms, a transport record may need to explain:
- pre-dispatch storage conditions
- packing or dispatch preparation exposure
- loading delay
- vehicle, container or box monitoring where configured
- route or lane context when configured
- carrier, courier or receiving transfer point
- route delay
- receiving delay
- temporary QA hold
- whether the shipment needs quarantine, deviation review or product disposition.
A passive data logger may provide a temperature file after delivery. That can be useful. Active GDP temperature monitoring becomes more useful when the team needs to know about an issue while the route is still active.
KRYOS can help where transport monitoring is configured by connecting route or monitored transport-point readings with alerts, acknowledgements, response notes and exports. It should not be described as a transport management system, inventory system or chain-of-custody platform unless those functions are explicitly supported in the implementation.
Alerts and excursions: when the record becomes evidence
GDP temperature monitoring requirements are not satisfied by collecting numbers alone. When a temperature excursion occurs, the record becomes part of a quality review.
A useful excursion record should include:
- the monitored point
- configured threshold
- event start and end
- duration
- minimum and maximum exposure
- too-warm or too-cold context
- alarm state
- responsible owner or team
- acknowledgement
- escalation context
- response notes
- recovery context
- report or export.
This is where many workflows break down. Temperature traces, emails, phone notes, screenshots, logger files and deviation records can end up in separate places. Later, a quality team may need to rebuild the event manually.
KRYOS supports GDP-oriented excursion review by keeping the monitoring record, alert context, acknowledgement, response notes and exportable evidence closer together.
The boundary matters. KRYOS provides environmental evidence. The customer’s quality system decides how the excursion is classified, whether a deviation is opened, whether CAPA is required and what happens to the product.
Returns and quarantine need condition history too
GDP monitoring does not end after dispatch or delivery. Returns, rejected deliveries and quarantine areas can create their own temperature questions.
Common examples include:
- a customer returns product after uncertain handling
- a delivery is rejected and placed on hold
- a shipment arrives after a temperature alarm
- returned stock waits for QA review
- product is quarantined pending manufacturer advice
- stock awaits disposal or return-to-stock decision.
The temperature history during this review period can matter. A product may already be questionable, but it still needs to be stored under suitable conditions until the business decides what happens next.
KRYOS can help monitor returns, quarantine and temporary hold areas where configured. It can preserve readings, incidents and reports, but it does not decide acceptance, rejection, disposal or return to stock.
Calibration, sensors and measurement context
GDP-oriented reviewers may ask whether the measurement record is reliable. That makes sensor identity, probe placement, device health and calibration context important.
A good monitoring setup should consider:
- which sensor or probe measured the condition
- where the probe was placed
- whether the device was suitable for the monitored point
- whether calibration or certificate context is available
- whether device health and battery state are visible
- how recalibration or replacement is handled
- whether records remain linked to the monitored asset.
Temperature mapping may also be relevant for storage areas. The WHO technical supplement on temperature and humidity monitoring systems describes mapping as documented measurement of temperature and humidity distribution in a storage area, including identification of hot and cold spots. Monitoring software can support the evidence layer, but the customer remains responsible for qualification, mapping decisions and validation where required.
Temperature mapping in pharma: how it relates to monitoring
Temperature mapping in pharma is usually a documented study of how temperature and, where relevant, humidity behave across a room, chamber, warehouse zone or transport space. It is different from day-to-day continuous monitoring. Mapping helps decide where sensors should be placed, which points are warm or cold, and whether the space can be used for the intended pharmaceutical storage condition.
Thermal mapping is often used as a near-synonym. In practice, thermal mapping pharma searches, thermal mapping in pharmaceuticals workflows and broader thermal mapping questions usually point to the same operational boundary: a documented study defines the temperature profile, then a monitoring system preserves routine evidence after the mapped space is in use.
For teams researching temperature mapping in pharmaceutical industry workflows, the practical question is not only where to put sensors during the mapping study. It is also what happens after the study is complete. A mapped storage area still needs ongoing monitoring, alert ownership, deviation records and periodic review.
A temperature mapping protocol in pharma is usually owned by the customer’s quality or validation process. It may define:
- the scope of the room, chamber, warehouse zone or transport space
- the number and placement of mapping sensors or data loggers
- the loaded, empty or operating condition to be tested
- the study duration and sampling interval
- the acceptance criteria and review method
- the actions required when warm spots, cold spots or unstable points are found
- the monitoring locations to use after the mapping study.
Temperature mapping data loggers, sensors and routine monitoring
Temperature mapping data loggers and mapping sensors are typically used for the study itself. A data logger for temperature mapping records values at planned positions so the quality or validation team can identify hot spots, cold spots and unstable locations. A thermal mapping sensor should be suitable for the temperature range, sampling interval and placement defined in the protocol.
Some teams shorten this work to temp mapping, but the same boundary still applies. Mapping equipment supports the study; routine monitoring equipment supports day-to-day control after the study. KRYOS is designed for the ongoing layer: sensor identities, probe placement, live readings, alerts, reports and audit logs tied to the monitored point after the mapping decision has been made.
When people search for temperature mapping guidelines for pharmaceutical industry use, they are usually looking for this boundary: mapping and qualification decide whether the space and sensor positions are suitable; continuous monitoring then preserves the operational evidence over time.
KRYOS does not replace the customer’s mapping protocol, qualification decision or validation report. It can support the follow-up monitoring layer after mapping by keeping sensor identities, probe placement, readings, alerts, response notes, reports and audit logs connected to the monitored point. The related sensors and probes, installation and validation and reports and audit logs pages explain the operational monitoring layer in more detail.
Reports and exports: what GDP review needs later
GDP temperature monitoring records should be retrievable. A record that exists but cannot be found quickly is not useful during a quality review, customer question, self-inspection or audit.
Reports and exports may need to show:
- date range
- monitored site, room, route, shipment, asset or zone
- temperature and humidity history where relevant
- threshold configuration
- alarms and incident timeline
- event duration
- min/max exposure
- acknowledgement
- response notes
- sensor or probe context
- export history when configured.
This is the difference between a raw temperature log and a review-ready monitoring record. A raw log shows values. A review-ready record explains the event.
KRYOS helps teams export records for GDP-oriented review without rebuilding evidence from paper logs, data logger files, emails, screenshots and separate notes. The related cold-chain temperature logs and audit-ready temperature records pages explain this documentation layer in more detail.
What KRYOS supports in a GDP-oriented workflow
KRYOS can support pharmaceutical temperature monitoring compliance workflows by connecting:
- continuous temperature history
- humidity history where relevant
- configured thresholds
- high and low alerts
- disconnection notifications where configured
- alert owners
- acknowledgements
- response notes
- incident timelines
- duration and min/max exposure
- sensor and probe context
- reports and exports
- storage, transport, return or quarantine context when configured.
This makes KRYOS relevant for wholesalers, distributors, pharmaceutical logistics teams, outsourced storage providers, quality teams, Responsible Person workflows, warehouse teams and transport operations.
It is still not the GDP quality system. KRYOS does not replace SOPs, staff training, supplier qualification, deviation handling, CAPA, product disposition, route qualification, validation or final sign-off.
A safe way to think about the boundary is:
KRYOS preserves the environmental evidence. Your quality system keeps the GDP decision.
GDP temperature monitoring checklist
A practical GDP temperature monitoring process should define:
- which products and storage conditions apply
- which rooms, assets, vehicles, routes or storage points need monitoring
- upper and lower alarm limits
- humidity limits where relevant
- alert delays and escalation paths
- responsible owners
- response-note expectations
- calibration and sensor documentation
- transport and responsibility-transfer record needs
- returns and quarantine monitoring
- report and export requirements
- retention requirements for monitoring records
- how excursions are reviewed inside the quality system.
This checklist should be adapted to the product, operation, country, SOPs and quality requirements.
Conclusion: GDP monitoring is about evidence continuity
GDP temperature monitoring requirements are not only about collecting temperature readings. They are about maintaining suitable conditions and preserving the evidence needed to explain what happened across storage, transport, responsibility transfers, returns, quarantine and review.
The strongest monitoring workflows keep the record connected: monitored point, required condition, threshold, alert, owner, response, exposure, report and quality review.
If your team needs GDP-oriented temperature monitoring with active alerts, incident context and exportable records, review KRYOS GDP temperature monitoring.
Need GDP-oriented temperature records?
See how KRYOS preserves monitoring evidence for controlled storage, transport context, deviations, responsibilities, and review.
